Tourmaline Bio Reports Positive Trial Results and Strong Cash Position

Tourmaline Bio, Inc. ( (TRML) ) has released its Q2 earnings. Here is a breakdown of the information Tourmaline Bio, Inc. presented to its investors.

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for patients with immune and inflammatory diseases, with a particular emphasis on cardiovascular and thyroid eye diseases. In its latest earnings report, Tourmaline Bio announced positive topline results from its Phase 2 TRANQUILITY trial of pacibekitug, showcasing significant reductions in high-sensitivity C-reactive protein with quarterly dosing. The company also highlighted its financial position, with cash reserves expected to support operations into the second half of 2027.

The TRANQUILITY trial results are a significant milestone for Tourmaline Bio, demonstrating pacibekitug’s potential as a best-in-class IL-6 inhibitor. The trial achieved over 85% reductions in hs-CRP from baseline, marking it as the first IL-6 inhibitor to do so with quarterly dosing. Tourmaline is also preparing for a Phase 2 proof-of-concept trial in abdominal aortic aneurysm and planning a Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease.

Financially, Tourmaline reported a net loss of $23.1 million for the second quarter of 2025, an increase from the previous year, attributed to higher research and development expenses. Despite this, the company maintains a strong cash position of $256.4 million, which is expected to fund ongoing and future clinical trials.

Looking ahead, Tourmaline Bio remains optimistic about its pipeline, with plans to expand pacibekitug into additional indications and continue its development in cardiovascular inflammation and thyroid eye disease. The company’s strategic focus on advancing its clinical trials and maintaining financial stability positions it well for future growth.